Glutamate and α-ketoglutarate: Key Players in Glioma Metabolism

Overview

Journal Amino Acids

Specialty Biochemistry

Date 2016 Oct 19

PMID 27752843

Citations 68

Authors

Andreas Maus

Godefridus J Peters

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM), or grade IV astrocytoma, is the most common type of primary brain tumor. It has a devastating prognosis with a 2-year-overall survival rate of only 26 % after standard treatment, which includes surgery, radiation, and adjuvant chemotherapy with temozolomide. Also lower grade gliomas are difficult to treat, because they diffusely spread into the brain, where extensive removal of tissue is critical. Better understanding of the cancer's biology is a key for the development of more effective therapy approaches. The discovery of isocitrate dehydrogenase (IDH) mutations in leukemia and glioma drew attention to specific metabolic aberrations in IDH-mutant gliomas. In the center of the metabolic alterations is α-ketoglutarate (αKG), an intermediate metabolite in the tricarboxylic acid (TCA) cycle, and the associated amino acid glutamate (Glu). This article highlights the role of these metabolites in glioma energy and lipid production and indicates possible weak spots of IDH-mutant and IDH-wt gliomas.

Citing Articles

The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies.

Krawczyk A, Sladowska G, Strzalka-Mrozik B Cancers (Basel). 2025; 17(5).

PMID: 40075568 PMC: 11899293. DOI: 10.3390/cancers17050719.

Hyaluronic Acid Influences Amino Acid Metabolism via Differential L-Type Amino Acid Transporter 1 Expression in the U87-Malignant Glioma Cell Line.

Bale A, Thammineni S, Bhargava R, Harley B Adv Nanobiomed Res. 2025; 4(12).

PMID: 40017591 PMC: 11864772. DOI: 10.1002/anbr.202400107.

Bulk and single-cell transcriptome revealed the metabolic heterogeneity in human glioma.

Xiao Y, Zhao M, Wang R, Liu L, Xiang C, Li T Heliyon. 2025; 11(1):e41241.

PMID: 39844970 PMC: 11750464. DOI: 10.1016/j.heliyon.2024.e41241.

Molecular characterization and computational analysis of a highly specific L-glutaminase from a marine bacterium Bacillus australimaris NIOT30.

Thenmozhi Kulasekaran N, Vanlalrovi , Subramanian L, Lee J, Gopal D, Marimuthu J Sci Rep. 2024; 14(1):26676.

PMID: 39496784 PMC: 11535052. DOI: 10.1038/s41598-024-77959-6.

Construction of a Prognostic Model for Mitochondria and Macrophage Polarization Correlation in Glioma Based on Single-Cell and Transcriptome Sequencing.

Chen P, Wang H, Zhang Y, Qu S, Zhang Y, Yang Y CNS Neurosci Ther. 2024; 30(11):e70083.

PMID: 39491527 PMC: 11532235. DOI: 10.1111/cns.70083.

References

DeBerardinis R, Cheng T . Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2009; 29(3):313-24. PMC: 2809806. DOI: 10.1038/onc.2009.358. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Ekstrand A, James C, Cavenee W, Seliger B, Pettersson R, Collins V . Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991; 51(8):2164-72. View

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P . Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324(5924):261-5. PMC: 3251015. DOI: 10.1126/science.1170944. View

Parker S, Metallo C . Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015; 152:54-62. PMC: 4489982. DOI: 10.1016/j.pharmthera.2015.05.003. View

He X, Huang Q, Qiu X, Liu X, Sun G, Guo J . LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells. Int J Biol Macromol. 2014; 72:1081-9. DOI: 10.1016/j.ijbiomac.2014.10.021. View

van Lith S, Navis A, Verrijp K, Niclou S, Bjerkvig R, Wesseling P . Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?. Biochim Biophys Acta. 2014; 1846(1):66-74. DOI: 10.1016/j.bbcan.2014.04.004. View

Babic I, Anderson E, Tanaka K, Guo D, Masui K, Li B . EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013; 17(6):1000-1008. PMC: 3679227. DOI: 10.1016/j.cmet.2013.04.013. View

10.

Masui K, Cavenee W, Mischel P . mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab. 2014; 25(7):364-73. PMC: 4077930. DOI: 10.1016/j.tem.2014.04.002. View

11.

Busek P, Stremenova J, Sromova L, Hilser M, Balaziova E, Kosek D . Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. Int J Biochem Cell Biol. 2012; 44(5):738-47. DOI: 10.1016/j.biocel.2012.01.011. View

12.

Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T . mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013; 18(5):726-39. PMC: 3840163. DOI: 10.1016/j.cmet.2013.09.013. View

13.

Luo H, Chen Z, Wang S, Zhang R, Qiu W, Zhao L . c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. Brain. 2015; 138(Pt 12):3654-72. DOI: 10.1093/brain/awv287. View

14.

Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

15.

Dasgupta B, Yi Y, Hegedus B, Weber J, Gutmann D . Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res. 2005; 65(21):9843-50. DOI: 10.1158/0008-5472.CAN-05-1842. View

16.

Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A . Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One. 2011; 6(10):e26057. PMC: 3198433. DOI: 10.1371/journal.pone.0026057. View

17.

Metallo C, Gameiro P, Bell E, Mattaini K, Yang J, Hiller K . Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011; 481(7381):380-4. PMC: 3710581. DOI: 10.1038/nature10602. View

18.

Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View

19.

Bak L, Schousboe A, Waagepetersen H . The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006; 98(3):641-53. DOI: 10.1111/j.1471-4159.2006.03913.x. View

20.

Guo P, Nie Q, Lan J, Ge J, Qiu Y, Mao Q . C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem Biophys Res Commun. 2013; 441(1):186-90. DOI: 10.1016/j.bbrc.2013.10.034. View